TKIs targeting the VEGF/VEGFR axis and immunotherapies targeting PD-1/PD-L1 have also become the standard treatment for metastatic ccRCC, and these combinations are now recommended as the first-line treatment for metastatic ccRCC according to the latest European recommendations (48). The gene discussed is KDR; the disease is nonpapillary renal cell carcinoma.